Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

regorafenib

This page shows the latest regorafenib news and features for those working in and with pharma, biotech and healthcare.

FDA clears Blueprint’s $32k-per-month GI cancer drug

FDA clears Blueprint’s $32k-per-month GI cancer drug

imatinib) and Pfizer’s Sutent (sunitinib), which are also available as generics, and Bayer’s Stivarga (regorafenib) which is still in patent.

Latest news

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting.

  • Another IO knockback as Tecentriq combo fails phase III trial Another IO knockback as Tecentriq combo fails phase III trial

    cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population. ... The results from IMblaze370 were consistent with this prior monotherapy experience, showing that

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Meanwhile, NICE has decided to remove Bayer’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the

  • Bayer's Nexavar backed by NICE for liver cancer Bayer's Nexavar backed by NICE for liver cancer

    Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the

More from news
Approximately 7 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Quick links

Infographics

Multimedia